Activiomics Announces Appointment of Non-Executive Chairman
News Mar 28, 2012
Activiomics Limited. has announced the appointment of industry leader Dr Trevor Nicholls to its Board as Non-Executive Chairman.
Dr Nicholls has over 30 years’ experience of building international businesses in the life science industry.
Currently he is CEO of CABI, a not-for-profit inter-governmental organization owned by 46 member countries worldwide and is Non-Executive Chairman of Oxford Nanopore Technologies, which is developing the GridION system, a new generation of electronic molecular analysis system for use in scientific research, personalized medicine, crop science, and security/defence.
His previous board roles include Chief Commercial Officer of Affymetrix Inc, based in California and, prior to that, CEO of Oxagen, a UK biotech company where he raised £50m over three venture-backed financing rounds and secured major commercial partnerships and academic collaborations.
Welcoming Dr Nicholls to the board, Dr Mark Warne, CEO of Activiomics, said: “I am confident that Trevor’s broad background in leading companies as they develop commercially will be invaluable to Activiomics as we move to the next phase of our development. He brings both a depth of international experience in commercial markets as well as a proven ability in raising finance for early-stage companies.”
Activiomics has developed innovative technologies using mass spectrometry to interrogate and interpret the activity of whole cell signalling pathways.
This technology is well-positioned to support personalized medicine initiatives, which are influencing increasing numbers of therapeutic programs.
The Company has recently met internal milestones resulting in a second tranche of funding from IP Group plc, (LSE: ipo) ("IP Group"), the developer of intellectual property based businesses. This follows an initial investment by IP Group in 2011.
Commenting on his appointment, Dr Nicholls said: “The unique nature of Activiomics’ approach to identifying robust biomarkers has already been validated by a number of partnerships with large pharmas, including with GlaxoSmithKline, UCB and Genentech, and the Company is well placed to take advantage of the rapidly growing personalized medicine market. I am delighted to be joining the Board at a time when it has received a financing injection on the back of this success and look forward to helping the company in its next stage of development.”
Protein Discovery Could Lead to Better Diagnosis of StressNews
Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.READ MORE
Tiny “Tornado” Boosts Performance of Electrospray Ionization Mass SpectrometryNews
Known as Dry Ion Localization and Locomotion (DRILL), the new device creates a swirling flow that can separate electrospray droplets depending on their size.READ MORE
Molecular Mechanism That Enable Neuronal Connections to Change With Development DiscoveredNews
Researchers from King's College London have discovered a molecular mechanism that enables neuronal connections to change through experience, thus fuelling learning and memory formation.READ MORE
Comments | 0 ADD COMMENT
11th Edition of International Conference on Proteomics 2018
Mar 22 - Mar 23, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018